Gilead's $1,000-a-pill hepatitis C drug breaks records, drives Q2 profit

With record-breaking revenue from its controversial hepatitis C drug, Gilead Sciences Inc. scored a second-quarter profit of nearly $3...
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.